Relief Therapeutics
About Relief Therapeutics
Relief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
YEAR FOUNDED:
1956
LEADERSHIP:
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
83 articles with Relief Therapeutics
-
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
6/16/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development to treat COVID-19-induced respiratory disorders, reported that its collaboration partner, NRx Pharmaceuticals, Inc., has announced additional results from the aviptadil U.S. Expanded Access Protocol.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
6/2/2021
RELIEF THERAPEUTICS Holding AG reported that its collaboration partner, NRx Pharmaceuticals, Inc., has announced that it has submitted an application to the U.S. Food and Drug Administration seeking Emergency Use Authorization for the use of aviptadil in the treatment of critical COVID-19 in patients with respiratory failure.
-
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
5/28/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19 induced respiratory disorders, announced the appointment of Taneli Jouhikainen, M.D., MBA, to the newly created position of Chief Operating Officer, effective June 1, 2021.
-
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
5/27/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, gives notice of the Annual General Meeting of shareholders to be held on June 18, 2021.
-
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
5/25/2021
Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding AG announced the outcome of Acer’s pre-New Drug Application meeting with the U.S. Food and Drug Administration for ACER-001 for the treatment of Urea Cycle Disorders.
-
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
5/18/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, provided an update on the development of ACER-001, a proprietary powder formulation of sodium phenylbutyrate designed to be both taste-masked and immediate release, in the lead indication, urea cycle disorders.
-
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
5/17/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19-induced lung injury, is pleased to see the recent announcement by APR Applied Pharma Research S.A. regarding the initiation of a pivotal clinical trial with its novel nasal spray, temporarily codenamed APR-AOS2020, a Class III medical device, in patients with mild COVID-19.
-
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
5/4/2021
Acquisition would further diversify Relief's pipeline with both commercial products and clinical-stage programs
-
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
4/19/2021
RELIEF THERAPEUTICS Holding AG, commented on certain statements made by NeuroRx, Inc., its collaboration partner for the development of RLF-100TM pursuant to that certain binding collaboration agreement, dated September 18, 2020, in Amendment No. 1 to the Form S-4 of Big Rock Partners Acquisition Corp.'s that was filed on Friday, April 16, 2021.
-
NeuroRx Responds to Issues Raised by Relief Therapeutics Regarding ZYESAMI development
4/19/2021
The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a worldwide basis.
-
Relief Reports 2020 Financial Results and Provides Business Update
4/15/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19 induced lung injury, announced its 2020 financial results for the year ended December 31, 2020 and provided a business update.
-
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
4/7/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat COVID-19 induced respiratory disorders, announced the appointment of J.J. Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant effective April 01, 2021.
-
Relief Confirms Release of 60-Day Findings from Phase 2b/3 Clinical Trial of Intravenous RLF-100(TM) (aviptadil)
3/30/2021
RELIEF THERAPEUTICS today announced the release of 60-day results from the phase 2b/3 trial of intravenously administered RLF-100(TM) by its partner NeuroRx, Inc.
-
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
3/29/2021
NeuroRx, Inc. reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
3/22/2021
Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021
-
Relief Reports that NeuroRx has Announced Feasibility Collaboration with TFF Pharmaceuticals
3/15/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100 in advanced clinical development, announces that its partner, NeuroRx, Inc., has reported that work is underway to determine the feasibility of formulating RLF-100 as a dry powder using TFF Pharmaceuticals' Thin-Film Freezing technology.
-
Relief Announces CHF 10 Million Private Placement
3/12/2021
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced that it has entered into a definitive agreement with a single healthcare-dedicated U.S. institutional investor to purchase in a private placement 41,459,370 of Relief common stock at a purchase price of CHF 0.2412 per share.